Baseline quality of life and performance status as prognostic factors in patients with extensive-stage disease small cell lung cancer treated with pemetrexed plus carboplatin vs. etoposide plus carboplatin-Reference-Cited by-同舟云学术

Baseline quality of life and performance status as prognostic factors in patients with extensive-stage disease small cell lung cancer treated with pemetrexed plus carboplatin vs. etoposide plus carboplatin

Published:2012-12 Issue:3 Volume:78 Page:276-281
ISSN:0169-5002
Container-title:Lung Cancer
language:en
Short-container-title:Lung Cancer

Author:

Reck Martin,Thatcher Nick,Smit Egbert F.,Lorigan Paul,Szutowicz-Zielinska Ewa,Liepa Astra M.,Winfree Katherine B.,Peterson Patrick,Guba Susan C.,Socinski Mark A.

Funder

Eli Lilly and Company, Indianapolis, IN, USA

Publisher

Elsevier BV

Subject

Cancer Research,Pulmonary and Respiratory Medicine,Oncology

Reference23 articles.

1. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008;Ferlay;Int J Cancer,2010

2. Increasing chemotherapy in small-cell lung cancer: from dose intensity and density to megadoses;Crivellari;Oncologist,2007

3. Cancer facts & figures 2011;American Cancer Society,2011

4. Extensive stage small cell lung cancer;Niell;Curr Treat Options Oncol,2001

5. Twenty years of phase III trials for patients with extensive-stage small-cell lung cancer: perceptible progress;Chute;J Clin Oncol,1999

Cited by 26 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Evaluation of Efficacy and Safety in First‐Line Treatment Methods for Extensive‐Stage Small Cell Lung Cancer: A Comprehensive Comparative Study of Chemotherapy, Targeted Therapy Combined With Chemotherapy, and Immunotherapy Combined With Chemotherapy;The Clinical Respiratory Journal;2024-08

2. Pretreatment quality of life and survival in patients with lung cancer: a systematic review and meta-analysis;BMC Cancer;2024-04-18

3. Deciphering the Role of Immune-Checkpoint Inhibitors in Lung Cancer Treatment;Molecular Biomarkers for Cancer Diagnosis and Therapy;2024

4. Neutrophil-to-lymphocyte and platelet-to-lymphocyte ratios as prognostic biomarkers in limited-stage small-cell lung cancer: a meta-analysis;Future Oncology;2023-06

5. Pan‐cancer efficacy and safety of anlotinib plus PD‐1 inhibitor in refractory solid tumor: A single‐arm, open‐label, phase II trial;International Journal of Cancer;2023-05-08